Atopic dermatitis treatment has changed enormously in only a few years. Now researchers face a new problem: when several effective therapies are available, how do we determine which one is best for a particular patient?
France's GREAT-FRADEN national clinical research network highlighted this question in a September 2026 overview of advances in atopic dermatitis research and care. The network notes that new therapeutic options have substantially expanded treatment possibilities for people with moderate-to-severe atopic dermatitis.
That progress is significant.
For many years, systemic treatment options were comparatively limited and often relied on broad suppression of immune activity. Today, clinicians may choose between several targeted biologics and oral medicines acting on specific inflammatory pathways.
But more options also create more complicated decisions.
One patient may respond extremely well to a biologic targeting type 2 inflammation. Another may achieve better disease control with a JAK inhibitor. Some people prioritise itch relief, while others may be most affected by widespread skin lesions, repeated flares or treatment convenience.
This is why »personalisation of treatment strategies« has become a major research priority. Researchers want to understand whether clinical characteristics or biomarkers can predict which therapy is most likely to produce a strong response in an individual patient.
Another major challenge is understanding what happens outside tightly controlled clinical trials. Randomised trials are essential for determining whether treatments work and assessing safety, but participants are selected according to specific inclusion and exclusion criteria.
Real-world populations are more diverse. Patients may have several other medical conditions, use multiple medications, miss doses or remain on treatment for much longer than the controlled phase of a clinical trial.
GREAT-FRADEN therefore highlights »real-world evaluation« as another important direction for atopic dermatitis research. Long-term registries and observational studies can help answer questions such as how treatments perform over several years, why patients discontinue therapy and whether particular adverse events appear in routine clinical practice. The organisation also stresses that misconceptions about atopic dermatitis remain common.
Atopic dermatitis can coexist with asthma, allergic rhinitis and food allergy, but atopic dermatitis itself should not simply be understood as a skin allergy. The next chapter of atopic dermatitis science may therefore look different from the previous one.
The first major challenge was developing effective targeted medicines. The next is learning how to use them intelligently.
For patients, the ultimate goal is straightforward: less trial and error, faster access to effective therapy and treatment choices that reflect the individual person rather than only the diagnostic label.